My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 164

    1.

    Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant.

    Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H; DALI Study Group.

    Diabetes Care. 2003 Feb;26(2):427-32.PMID: 12547874 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of gender, hepatic lipase gene polymorphism and type 2 diabetes mellitus on hepatic lipase activity in Chinese.

    Tan KC, Shiu SW, Chu BY.

    Atherosclerosis. 2001 Jul;157(1):233-9.PMID: 11427226 [PubMed - indexed for MEDLINE]Related articles

    3.

    A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes.

    Hokanson JE, Cheng S, Snell-Bergeon JK, Fijal BA, Grow MA, Hung C, Erlich HA, Ehrlich J, Eckel RH, Rewers M.

    Diabetes. 2002 Apr;51(4):1208-13.PMID: 11916946 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

    Diabetes Atorvastin Lipid Intervention (DALI) Study Group.

    Diabetes Care. 2001 Aug;24(8):1335-41.PMID: 11473066 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.

    Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD.

    Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1723-9.PMID: 9812910 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.

    van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM; DALI Study Group.

    Diabetes Care. 2003 Apr;26(4):1216-23.PMID: 12663600 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women.

    Carr MC, Hokanson JE, Deeb SS, Purnell JQ, Mitchell ES, Brunzell JD.

    Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2701-7.PMID: 10559014 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Interaction effect of Serine447Stop variant of the lipoprotein lipase gene and C-514T variant of the hepatic lipase gene on serum triglyceride levels in young adults: the Bogalusa Heart Study.

    Xin X, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS.

    Metabolism. 2003 Oct;52(10):1337-42.PMID: 14564687 [PubMed - indexed for MEDLINE]Related articles

    9.

    Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.

    Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD.

    Circulation. 2001 Feb 13;103(6):792-8.PMID: 11171785 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

    Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O; 3T Study Investigators.

    Clin Ther. 2003 Jan;25(1):119-38.PMID: 12637115 [PubMed - indexed for MEDLINE]Related articles

    11.

    Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.

    Cenarro A, Artieda M, Gonzalvo C, Meriño-Ibarra E, Arístegui R, Gañán A, Díaz C, Sol JM, Pocoví M, Civeira F; ATOMIX Study Group.

    Am Heart J. 2005 Dec;150(6):1154-62.PMID: 16338252 [PubMed - indexed for MEDLINE]Related articles

    12.

    Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H; Diabetes Atorvastatin Lipid intervention (DALI) Study Group.

    Diabetes Care. 2004 Jun;27(6):1358-64.PMID: 15161788 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects.

    Grarup N, Andreasen CH, Andersen MK, Albrechtsen A, Sandbaek A, Lauritzen T, Borch-Johnsen K, Jørgensen T, Schmitz O, Hansen T, Pedersen O.

    J Clin Endocrinol Metab. 2008 Jun;93(6):2294-9. Epub 2008 Mar 25.PMID: 18364377 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients.

    Jansen H, Verhoeven AJ, Weeks L, Kastelein JJ, Halley DJ, van den Ouweland A, Jukema JW, Seidell JC, Birkenhäger JC.

    Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2837-42.PMID: 9409263 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.

    Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA.

    Atherosclerosis. 2004 Aug;175(2):325-31.PMID: 15262189 [PubMed - indexed for MEDLINE]Related articles

    16.

    A novel allele in the promoter of the hepatic lipase is associated with increased concentration of HDL-C and decreased promoter activity.

    Su Z, Zhang S, Nebert DW, Zhang L, Huang D, Hou Y, Liao L, Xiao C.

    J Lipid Res. 2002 Oct;43(10):1595-601.PMID: 12364543 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The T allele of the hepatic lipase promoter variant C-480T is associated with increased fasting lipids and HDL and increased preprandial and postprandial LpCIII:B : European Atherosclerosis Research Study (EARS) II.

    Jansen H, Chu G, Ehnholm C, Dallongeville J, Nicaud V, Talmud PJ.

    Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):303-8.PMID: 9974411 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Genetic variations of the hepatic lipase gene in Korean patients with coronary artery disease.

    Hong SH, Song J, Kim JQ.

    Clin Biochem. 2000 Jun;33(4):291-6.PMID: 10936588 [PubMed - indexed for MEDLINE]Related articles

    19.

    The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

    Zacharova J, Todorova BR, Chiasson JL, Laakso M; STOP-NIDDM Study Group.

    J Intern Med. 2005 Feb;257(2):185-93.PMID: 15656877 [PubMed - indexed for MEDLINE]Related articles

    20.

    Ethnic differences in hepatic lipase and HDL in Japanese, black, and white Americans: role of central obesity and LIPC polymorphisms.

    Carr MC, Brunzell JD, Deeb SS.

    J Lipid Res. 2004 Mar;45(3):466-73. Epub 2003 Dec 1.PMID: 14657196 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity